Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MetaVia Inc.NRBO · Entity 7947 | Director · 10% owner | January 13, 2020 | January 16, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MetaVia Inc.
Report date January 13, 2020 · Filed January 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.39 · Expires 2030-01-12 | Direct | 60,000 |
Reported balance
After 2020-01-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-13 · Grant · Acquired 60,000 · Balance 60,000 F1: The option vests in 36 equal monthly installments beginning on 2/13/2020, such that the option will be fully vested on the third anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 36 equal monthly installments beginning on 2/13/2020, such that the option will be fully vested on the third anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 13, 2020 Filed Jan 16, 2020 00:15 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantNon-qualified stock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001683168-20-000163 · ownership.xml · derivative · entry 1 Oh Jeong Gyun · CIK 0001794777 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-01-12 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments beginning on 2/13/2020, such that the option will be fully vested on the third anniversary of the date of grant. Read SEC document |
| December 30, 2019 Filed Jan 3, 2020 02:53 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 240,051 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-20-000015 · ownership.xml · nonDerivative · entry 2 Oh Jeong Gyun · CIK 0001794777 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by spouse. Disclosed balance after: 240,051 F3 · price: Received in connection with the closing of the Merger in exchange for 210,000 shares of common stock of NeuroBo issued upon the conversion of Series B preferred stock of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, held by the spouse of Jeong Gyun Oh. F4 · price: In connection with the closing of the Merger, each share of NeuroBo common stock was exchanged for 1.1431 shares of the Issuer's common stock. F5 · ownership.nature: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 30, 2019 Filed Jan 3, 2020 02:53 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 1,817,842 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-20-000015 · ownership.xml · nonDerivative · entry 1 Oh Jeong Gyun · CIK 0001794777 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by JK BioPharma Solutions, Inc. Disclosed balance after: 1,817,842 F1 · price: Received in connection with the closing of the merger of GR Merger Sub Inc., a wholly-owned subsidiary of the Issuer, with and into NeuroBo Therapeutics, Inc. (formerly NeuroBo Pharmaceuticals, Inc.) ("NeuroBo") on December 30, 2019, in exchange for (i) 1,000,000 shares of common stock of NeuroBo and (ii) 590,274 shares of common stock of NeuroBo issued upon conversion of convertible promissory notes of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, held by JK BioPharma Solutions, Inc. F4 · price: In connection with the closing of the Merger, each share of NeuroBo common stock was exchanged for 1.1431 shares of the Issuer's common stock. F2 · ownership.nature: Mr. Oh is the President and Chief Executive Officer of JK BioPharma Solutions, Inc., and as such has voting and investment control over the shares held by JK BioPharma Solutions, Inc. F5 · ownership.nature: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.